3 Cardiac and Gastro Brands Specialist, Latin America Generics Seller and Contract Formulations Maker Stocks With a Strong Future Roadmap: JB Chemicals and Pharmaceuticals, Caplin Point Laboratories and Innova Captab

Brand, Latin America and contract pharma stocks bring together companies with a visible plan for the years ahead. JB Chemicals and Pharmaceuticals, Caplin Point Laboratories and Innova Captab cover a cardiac and gastro brands specialist, a Latin America generics seller and a contract formulations maker.

This list covers three brand, Latin America and contract pharma stocks with complete current figures: JB Chemicals and Pharmaceuticals, Caplin Point Laboratories and Innova Captab. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Brand, Latin America and Contract Pharma Stocks?

Brand, Latin America and contract pharma stocks are listed drug makers that sell brands in India, supply generics to Latin America and make formulations for other companies. Their earnings depend on prescriptions, export markets, plant quality and new launches.

Brand, Latin America and Contract Pharma Stocks at a Glance

On valuation, Caplin Point Laboratories trades at a P/E below the industry P/E, while JB Chemicals and Pharmaceuticals and Innova Captab trade above it, which reflects the growth the market already expects. Readers comparing brand, Latin America and contract pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in brand, Latin America and contract pharma stocks can use the coming numbers to test whether growth is holding.

Why Do Brand, Latin America and Contract Pharma Stocks Have a Strong Roadmap in India?

Brand, Latin America and contract pharma stocks have a strong roadmap in India because wider healthcare access, growing demand for affordable medicines and outsourced manufacturing keep widening the revenue base.

• Brand strength. Established brands retain loyal prescribers.
• Emerging markets. Latin American sales add steady orders.
• Contract work. Other drug companies outsource formulations.

Why JB Chemicals and Pharmaceuticals Features Among These Brand, Latin America and Contract Pharma Stocks

Among the brand, Latin America and contract pharma stocks on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.

The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8.

Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.

Roadmap: The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

What to watch: Monitor the growth of key domestic brands and the order flow in contract manufacturing.

Why Caplin Point Laboratories Features Among These Brand, Latin America and Contract Pharma Stocks

Among the prescription brand seller shares on this list, Caplin Point Laboratories, based in Chennai, sells branded generic medicines in Latin America and other emerging markets and has built a regulated-market business through its sterile injectables arm.

Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%.

In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0.

Roadmap: The company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.

What to watch: Follow new US product approvals and currency trends in Latin American markets.

Why Innova Captab Features Among These Brand, Latin America and Contract Pharma Stocks

Among the three companies on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.

In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.

Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.

Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.

JB Chemicals and Pharmaceuticals vs Caplin Point Laboratories vs Innova Captab on Key Financials

The table below sets the three brand, Latin America and contract pharma stocks side by side on revenue, profit and margin, using reported figures.

Caplin Point Laboratories posts the highest return on equity in this group at 17.9%. JB Chemicals and Pharmaceuticals has the largest FY26 revenue at Rs 4,208 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with brand, Latin America and contract pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Brand, Latin America and Contract Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these brand, Latin America and contract pharma stocks, the main points are: Long-term prescription brand seller shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory checks. Plant inspections can affect approvals.
• Currency moves. Export earnings move with local currencies.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter brand, Latin America and contract pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Brand, Latin America and Contract Pharma Stocks

Brand, Latin America and contract pharma stocks suit investors who prefer to study business strength before price moves. JB Chemicals and Pharmaceuticals, Caplin Point Laboratories and Innova Captab each have a clear plan to grow. Based on the 23 October 2026 close, JB Chemicals and Pharmaceuticals trades at Rs 2,408.9, Caplin Point Laboratories at Rs 2,222 and Innova Captab at Rs 987.3. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these brand, Latin America and contract pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track brand, Latin America and contract pharma stocks, set price alerts and get research-backed stock ideas.

What are brand, Latin America and contract pharma stocks?

Ans. Brand, Latin America and contract pharma stocks are listed drug makers that sell brands in India, supply generics to Latin America and make formulations for other companies. Their earnings depend on prescriptions, export markets, plant quality and new launches. This list looks at three of them, JB Chemicals and Pharmaceuticals, Caplin Point Laboratories and Innova Captab, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.

Which brand, Latin America and contract pharma stocks are covered in this list?

Ans. This list covers JB Chemicals and Pharmaceuticals, Caplin Point Laboratories and Innova Captab. Based on the 23 October 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Caplin Point Laboratories at Rs 2,222 and Innova Captab at Rs 987.3. Their return on equity ranges from 12.9% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.3% to 19.5%.

Why do brand, Latin America and contract pharma stocks have a strong future roadmap in India?

Ans. Brand, Latin America and contract pharma stocks have a strong roadmap in India because wider healthcare access, growing demand for affordable medicines and outsourced manufacturing keep widening the revenue base. The main drivers are as follows. Brand strength. Established brands retain loyal prescribers. Emerging markets. Latin American sales add steady orders. Contract work. Other drug companies outsource formulations. Together these factors give the companies on this list a visible path for growth over the coming years.

How has JB Chemicals and Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

How has Caplin Point Laboratories performed financially?

Ans. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.

How has Innova Captab performed financially?

Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What risks should investors check before buying brand, Latin America and contract pharma stocks?

Ans. Investors should check a few risks before buying brand, Latin America and contract pharma stocks. Regulatory checks. Plant inspections can affect approvals. Currency moves. Export earnings move with local currencies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of brand, Latin America and contract pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.